Steve Bales Announced as President & CEO of Global-Med Technologies Group

Share this story with your network

Sarasota, FL, March 22, 2011 –(PR.com)– The Board of Directors of Global-Med Technologies Group, Inc. (GTG) announced the promotion of Steve Bales from Executive Vice President to President & CEO. Bales brings more than 30 years of medical device experience to this position in the areas of sales, product and distributor development, and senior management. He has a highly successful track record in growing medical device business units and initiatives through his extensive surgeon contacts, technology research & development, and strategic product positioning. The Board believes this promotion will increase value for shareholders by reinforcing GTG’s focus on the business side of medical devices.

Bales joined GTG in 2009 as Executive Vice President where he has been responsible for strategic project initiatives including development of the Company’s subsidiaries’ medical device technologies. He has been the leading liaison between GTG, surgeon developers, and distribution channels. During his career he has also consulted with domestic and European companies to initiate marketing, distribution, and new business strategies.

“We believe that Mr. Bales is a well-known and trusted medical device executive who continues to maintain many contacts with leading surgeons, medical companies, and sales groups,” said GTG Board member Robert Stopanio. “This represents a great stride forward in organizational development and we are delighted to have Steve’s extensive experience, wisdom, and guidance now leading the Company. The Board is confident that Steve’s exceptional entrepreneurial talents will provide the professional leadership for the growth and development of GTG and its subsidiaries. It is significant to note that GTG now has a well-known medical device planning, development, and sales expert to lead the day-to-day efforts of the Company. We look forward to growing GTG’s market share in the United States and international markets under Mr. Bales’ leadership.”

Prior to joining GTG, Bales held many industry-specific positions including Senior Consultant for Unified Strategies, Inc.; Division Director, Spine, at Encore Medical Corporation; Vice President of Sales at Protek, Inc., a Swiss orthopedic device company; and Vice President of Sales at DePuy, Inc., a Johnson & Johnson company.

About Global-Med Technologies Group, Inc. (GTG)
GTG is a technologies-driven, research-based private holding group exclusively focused on the orthopedic and musculoskeletal device sector. Our goal is to provide surgeons and health professionals with clinically relevant, innovative and cost-effective products that improve the quality of life for patients with a focus on devices and procedures that are minimally invasive in nature and therefore, less traumatic to the patient. GTG’s subsidiary product lines include biologic, orthopedic, spine, neurosurgical and other musculoskeletal devices and/or procedures designed for repair, reconstruction, and regeneration of bones, joints, and surrounding soft tissues. GTG is researching and developing non-invasive procedures and treatments for osteoporosis and other age related degenerative diseases. We are committed to the development of pre-operative, operative, and post- operative procedures, devices, and monitoring systems that reduce cost while providing surgeon and patient less traumatic surgical intervention options.

For more information, the GTG website is located at www.global-med.us.com

Media inquiries: Scott Reynolds, scottr@global-med.us.com.

Forward-Looking Statements
Statements in this press release other than statements of historical fact, including statements regarding the Company’s plans, beliefs and estimates as to projections are “forward-looking statements.” Such statements are subject to certain risks and uncertainties and actual results could differ materially from expected results. These forward-looking statements represent the Company’s judgment as of the date of this release. The Company does not undertake to update, revise or correct any forward-looking statements.

Leave a Comment

Your email address will not be published. Required fields are marked *

*